Advancing Pediatric Cancer Monitoring Through NGS-Based Proteomics

Explore how next-generation sequencing-based proteomics is revolutionizing pediatric cancer monitoring through liquid biopsy analysis in this 31-minute webinar. Learn how researchers from The ACRF Spatial Immune Oncology Research (ASpIREe) and Child Cancer Liquid Biopsy Programs (CCLBP) at the Children's Cancer Institute, Sydney utilized a multiomics approach to decode the immune landscape of pediatric cancers without invasive tumor biopsies. Discover how Olink® Explore HT was used to profile serum from 88 pediatric patients with central nervous system (CNS) and extracranial tumor types, alongside whole-genome and RNA sequencing data from the ZERO Childhood Cancer Program. Understand how this multiomics analysis enabled investigation of potential tumor-specific plasma markers in blood, identifying distinct protein expression changes unique to brain tumors, neuroblastoma, and sarcomas. Examine how tumor subtype-specific blood biomarkers can be detected even in small cohorts and how integrating Olink proteomics analysis with cellular immune profiling and multiomics data reveals how immune signals in blood can mirror activity within the tumor immune microenvironment (TIME). Gain insights into how these findings could revolutionize biomarker identification and monitoring, guide immunotherapy decisions, and ultimately personalize care for young cancer patients. The presentation is delivered by Dr. Tom Mincherton, a research officer with expertise in high dimensional flow cytometry, imaging flow cytometry, and liquid biopsy sample analysis, who is currently applying his expertise to pediatric cancer research at the Children's Cancer Institute Australia.